Objective-To determine if susceptibility to Behcet's disease (BD) is associated with polymorphism of HLA-DRB1, HLA-DQB1, and TAPI and TAP2 genes. Methods-Fifty eight Spanish BD patients and 116 ethnically matched unrelated healthy subjects were typed at the HLA-DRB1 and HLA-DQB1 loci using polymerase chain reaction/sequence specific oligotyping (PCR/SSO). TAPI and TAP2 alleles were assigned using amplification refractory mutation system-PCR. Results-TAP1C was absent in BD patients, but was found in 12 10/% of control subjects (pc., < 0-05; relative risk = 0.06).
A large number of immunogenetic studies in normal and patient populations have demonstrated that genes within the major histocompatibility complex (MHC), or closely linked to it, play a major role in the development of many human diseases. Behcet's disease (BD) is a multifaceted syndrome of unknown origin, characterised by oral aphthae, ocular lesions, cutaneous vasculitis, and genital ulcerations as major symptoms, and by arthritis, meningoencephalitis, vascular, and visceral involvement as minor symptoms. Although the aetiology and pathogenesis of BD remain totally unknown, BD is associated with specific HLA alleles, the HLA-B5 1 antigen being the genetic marker most strongly associated with the disease in various ethnic groups.' 2 HLA-B51 is also a well defined marker of the ocular form of BD.1 2 However, this association is not absolute, raising the possibility that it could result from linkage disequilibrium with other loci. It is thus of interest to investigate the involvement of other genes located in the human MHC, in BD susceptibility.
Stable cell surface presentation of peptides by HLA class I molecules requires active transport of antigenic peptides across the endoplasmic reticulum (ER) by products of two genes, TAP1 and TAP2 (transporters associated with antigen processing), which map in the MHC class II region,3 and are members of the ABC (ATP binding cassette) transporter superfamily. Several coding variants of the TAPI and TAP2 genes have been described, 4 5 and it is possible that differences in human TAP gene products could cause alterations in the peptides presented by class I molecules. (table 1) . Table 2 shows the frequencies of TAPI and TAP2 alleles in both groups. TAP 1 C was negatively associated with the disease: it was absent in BD patients, but present in 14 of 116 control subjects (12-1%) (pcorr<005, RR= 0 06). Two of 18 HLA-B51 positive controls were typed as TAP1C (data not shown).
When different combinations of HLA class II antigens and TAP alleles were analysed, the frequency of DQB1*0501/TAP2B was found to be increased in patients compared with healthy controls (table 3) (A = 0-132, pcorr < 004). It was not possible to state if there was an association between HLA-B51 and TAP2B (or DQB1*0501) in patients and controls because the sample size was too small to allow statistical analysis (three individuals HLA-B51/DQB1*0501 in the patient group and four in the control group).
Discussion
The results of this study agree with previous evidence that susceptibility to BD is influenced by genetic factors mapped within the HIA gene region, B51 being the HIA genetic marker most strongly correlated with disease susceptibility. The results also confirm the strong association of the ocular type of BD with HLA-B51 specificity. No HLA class I antigen other than B51 was shown to be associated with BD, indicating that genetic predisposition to the disease is mainly controlled by HLA-B51 or by some defect(s) in a gene around the HLA-B region in linkage disequilibrium with B51. However, as this association was not complete, additional genetic or environmental factors may be implicated in pathogenesis of Behset's disease.
The transmembrane domains of TAPI and TAP2 are thought to form a pore through which antigenic peptides are translocated from the cytosol to the ER,`3 and this transport seems to be influenced by either the sequence of the peptide, or the polymorphism of the TAP subunits.5 The absence of TAPi C in the population of BD patients studied may be explained in terms of this function of TAP molecules: individuals possessing the TAP1C allele may be presumed to have a reduced ability to translocate some peptides involved in the development of BD and thus derive protection from the disease. The absence of TAP1C in BD patients does not seem to be attributable to the increased number of HLA-B51 individuals in this group, or to the existence of a hypothetical linkage disequilibrium between HLA-B51 and TAPIC in the Spanish population, because we found several HLA-B51/TAP 1 C subjects in the control population. However, the size of the sample was too small for statistical analysis. We cannot exclude the possibility that some BD patients typed as TAPlA/TAPIB were TAPIC/ TAP1D, but this seems unlikely because TAP 1 D has not been observed at all in previous studies.5 The same is likely to be true for healthy controls.
Studies performed in different populations of patients with BD have shown a decrease in the frequency of HIA-DQB1*0501 among these patients. 2 The finding of a linkage disequilibrium between HLA-DQB 1*0501 and TAP2B in our patients may indicate that the gene conferring susceptibility to BD is inherited in association with this haplotype in the population studied, and raises the possibility that its inheritance as an extended haplotype that includes HLA-DQB1*0501 and TAP2B may apply more generally also. This linkage disequilibrium was not observed in our ethnically matched control population; however, in the UK population TAP2B/DR1 (DQB1*0501 has been observed.'4 An alternative explanation is that DQB1*0501 and TAP2B are not necessarily in haplotypic association but may act as trans cofactors in BD. From a practical point of view, this result provides an additional tool to identify individuals at greatest risk of the disease.
The biological mechanisms underlying the effect on disease susceptibility of the TAP2B allele in combination with the DQ5 antigen, and the protection conferred by TAPl C against Behqet's disease are still speculative and require further study. Elucidation of the constraints for peptide selection imposed by TAP may improve prediction of the epitopes likely to be derived from a particular antigen of interest. 
